Skip to Content
  • A 2.3 Billion Dollar Attention-Getter

    No sooner do I write another post about pharma marketing than Pfizer finds itself paying 3.2 2.3 billion dollars in fines for doing it improperly. 1.2 billion o… Read More
  • Ghostwriting

    As much as I defend the industry I work in, I have to talk about things that we do that I don’t think are so defensible. Another one of those has come up… Read More
  • Selling Zyprexa

    Well, this doesn’t look good for Lilly. A huge pile of court documents has been unsealed in the ongoing lawsuits about Zyprexa’s off-label promotion… Read More
  • Word For Word – But Why?

    I missed this a couple of months ago, but there was a paper withdrawn from the Journal of Organic Chemistry. The original is here, a contribution from the India… Read More
  • Merck, Elsevier, and Fakery

    I’ve been meaning to write about the latest advance in salesmanship, pioneered by Merck and Elsevier. As most of you will have heard, the two collaborated… Read More
  • No MAGIC Involved

    What a mess! Science has a retraction of a 2005 paper, which is always a nasty enough business, but in this case, the authors can’t agree on whether it should… Read More
Page 20 of 23« First...10...1819202122...Last »